Posters

Our initial experience with ocriplasmin in the treatment of vitreomacular traction

Poster Details

First Author: J.Moreira PORTUGAL

Co Author(s):    C. Teixeira   R. Goncalves   P. Coelho   T. Maio   F. Sampaio   P. Tenedorio              

Abstract Details



Purpose:

Ocriplasmin is a proteolytic enzyme approved for the treatment of vitreomacular traction (VMT). In this paper, we describe our experience with ocriplasmin.

Setting:

Department of Ophthalmology, Hospital Pedro Hispano, Porto, Portugal.

Methods:

Retrospective analysis of all patients with VMT treated with ocriplasmin injection from May 2016 through January 2017

Results:

Six eyes (5 patients) with focal VMT received intravitreal ocriplasmin. Our sample included 4 females (80%) and 1 male (20%), and the mean age at diagnosis was 75 years. In all cases, the presenting complaint was decreased visual acuity. Four eyes were phakic, and the remaining two eyes were pseudophakic. At baseline, the average VMT adhesion diameter was 396 ┬Ám. The average time from diagnosis to treatment with ocriplasmin was 10 months (range: 3 to 17 months). Overall, four eyes (66,7%) achieved successful VMT resolution. Mean time to resolution was 45,5 days (range: 2 to 120 days). Two cases had partial release of VMT at day 28, and only achieved complete VMT resolution after 58 and 120 days, respectively. All eyes that had VMT release had improved their mean visual acuity by 3/10. Only one patient experienced photopsia early after ocriplasmin injection, but resolved rapidly thereafter. No serious ocular side effects were observed.

Conclusions:

Although the small sample size of our study, ocriplasmin demonstrated to be a safe and effective option to treat VMT. In fact, the rate of nonsurgical VMT resolution was higher when compared to the original MIVI-TRUST study, and this was probably due to a careful patient selection. Similar to previous reports, our experience shows that favorable results can be observed long after the 28 days established to achieve the final outcome of ocriplasmin treatment, suggesting that one month might be too early for assessment of release of VMT, and longer follow-up may be needed after intravitreal ocriplasmin.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy